It has set a goal to be first in the urology prescription drug market, which is the leading market for dermatology prescription drugs in Korea. The growth rate is expected to increase with the launch of a combination drug that combines erectile dysfunction treatment and treatment for premature ejaculation next year.
Cho Yong-joon, CEO of Donggu Biopharmaceuticals, said on the 4th, “Through the combined drug for the treatment of premature ejaculation and erectile dysfunction, we will not only advance to the No.
Donggu Bio Pharm is developing a new improved drug that combines the treatment of erectile dysfunction and premature ejaculation with CTC Bio. It is a phase 3 clinical trial, and the patient has finished medication and is awaiting results. It plans to apply for product approval to the Food and Drug Safety Administration at the end of this year or early next year.
Donggu Biopharmaceuticals recorded a record performance, recording 96 billion won in sales and 10.2 billion won in operating profit in the first half of this year. Although many pharmaceutical companies suffered sales losses due to the COVID-19 pandemic, Donggu Bio Pharm managed to avoid the impact of COVID-19. This is because patients have been regularly visiting dermatology, the main market.
Sales of Dermotasone MLE, an itch treatment, and Cycrine, an immunosuppressant, are expected to increase by around 10% this year compared to the previous year. This is the reason why it is expected that this year’s record performance will be achieved without difficulty. Last year, it posted 155.1 billion won in sales and earned 8.1 billion in operating profit.
Since its listing in 2018, Donggu Biopharmaceuticals has increased its competitiveness in drug and specialty contract manufacturing (CMO), its main business divisions, and expanded research and development investment for four years. CEO Cho said, “Based on the baseline period, we have entered a full growth cycle.”
Reporter Lee Ji-hyun bluesky@hankyung.com
/cloudfront-ap-northeast-1.images.arcpublishing.com/chosun/JH3FDCPTGNEOXJM4J3FOM27SJQ.jpg?fit=300%2C300&ssl=1)
